Kurs
+1,63%
Kurs
+1,63%
Open
9,85
High
10,40
Low
8,55
Close
9,35
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
Tid* | ||
2022-01-26 | - | Bokslutskommuniké 2021 |
2021-07-14 | - | Kvartalsrapport 2021-Q2 |
2021-06-30 | - | Årsstämma |
2021-05-27 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-11-11 | - | Kvartalsrapport 2020-Q3 |
2020-07-15 | - | Kvartalsrapport 2020-Q2 |
2020-06-22 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
2020-06-19 | - | Årsstämma |
2020-05-06 | - | Kvartalsrapport 2020-Q1 |
2020-02-19 | - | Bokslutskommuniké 2019 |
2019-11-13 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-31 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
2019-05-29 | - | Årsstämma |
2019-04-30 | - | Kvartalsrapport 2019-Q1 |
2019-02-13 | - | Bokslutskommuniké 2018 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-31 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
2018-05-30 | - | Årsstämma |
2018-02-08 | - | Bokslutskommuniké 2017 |
2017-11-24 | - | Extra Bolagsstämma 2017 |
2017-08-16 | - | Kvartalsrapport 2017-Q2 |
2017-05-16 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
2017-05-15 | - | Årsstämma |
2017-05-15 | - | Kapitalmarknadsdag 2017 |
2017-05-15 | - | Kvartalsrapport 2017-Q1 |
2017-02-08 | - | Bokslutskommuniké 2016 |
2016-11-16 | - | Kvartalsrapport 2016-Q3 |
2016-08-17 | - | Kvartalsrapport 2016-Q2 |
2016-05-20 | - | Årsstämma |
2016-05-20 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-11-25 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2014-11-26 | - | Kvartalsrapport 2014-Q3 |
2014-08-27 | - | Kvartalsrapport 2014-Q2 |
2014-05-27 | - | Kvartalsrapport 2014-Q1 |
2014-02-17 | - | Bokslutskommuniké 2013 |
2013-11-26 | - | Kvartalsrapport 2013-Q3 |
2013-08-27 | - | Kvartalsrapport 2013-Q2 |
2013-05-22 | - | Kvartalsrapport 2013-Q1 |
2013-02-28 | - | Bokslutskommuniké 2012 |
2012-11-15 | - | Kvartalsrapport 2012-Q3 |
2012-08-21 | - | Kvartalsrapport 2012-Q2 |
2012-05-16 | - | Kvartalsrapport 2012-Q1 |
2012-02-28 | - | Bokslutskommuniké 2011 |
2012-02-13 | - | Extra Bolagsstämma 2012 |
2011-11-17 | - | Kvartalsrapport 2011-Q3 |
2011-10-31 | - | Extra Bolagsstämma 2011 |
2011-08-18 | - | Kvartalsrapport 2011-Q2 |
2011-05-19 | - | Kvartalsrapport 2011-Q1 |
2011-02-25 | - | Bokslutskommuniké 2010 |
Beskrivning
Land | Norge |
---|---|
Lista | OAX Equities |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2020-02-19 08:15:10
Oslo, Norway (19 February 2020) - Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May 29th, 2019, and the option program related to defined operational objectives approved by the Board of Directors in 2019, the Board of Directors of NattoPharma has in board proceedings February 18th, 2020 granted a total of 155 000 options to executive management, other employees and strategic partners. Options are granted based on performance against defined criteria and metrics. The following persons on the executive management team have been granted options; Name Shares Granted Options Prior to Grant Options after Grant Owned Options Kjetil 300 50 000 225 100 275 100 Ramsøy, CEO 000 & CFO Other employees and partners have been granted a total of 105 000 options. The options have an exercise price equal the closing price on Oslo Axess on February 18[th], 2020, which is equal to NOK 9,20. The options granted are vested immediately and may be exercised up to and including March 31[st], 2023. Further, in conjunction with the hiring of the new Chief Financial Officer in NattoPharma the Board of Directors has in board proceedings February 18th, 2020 granted a total of 30,000 options to Robert Schrama who will start in the new position on March 9th, 2020. Mr. Schrama holds no shares or options in NattoPharma ASA prior to this grant. His total holding of shares and options following this grant is 30,000 options. The options will have an exercise price equal the closing price on Oslo Axess on March 9th, 2020. The options granted are fully vested on September 9th, 2020 and may be exercised up to and including March 31st, 2023. X X X For more information, please contact: Kjetil Ramsøy, CEO, NattoPharma E-mail: kjetil.ramsoy@nattopharma.com This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.